Table 1

Baseline characteristics of 30 patients (32 eyes) treated with intravitreal bevacizumab

Characteristic	Total (32 eyes)	Subfoveal (18 eyes)	Juxtafoveal (14 eyes)	p Value
Gender (M/F)	13/17
Age (years)	56.2±12.5	56.3±14.7	55.9±9.5	0.9^*
Axial length (mm)	29.9±2.3	30.5±2.7	29.2±1.4	0.1^*
Baseline BCVA (No of ETDRS letters)	30.1±15.6	21.4±10.3	41.3±14.2	<0.0001^*
Baseline CNV area (mm²)	0.63±0.71	0.88±0.84	0.28±0.16	0.008^*
Peripapillary atrophy area (mm²)	13.6±8.8	15.0±10.5	11.7±5.4	0.3^*
Duration of symptoms (months)	1.5±1.5	2.0±1.8	0.9±0.6	0.02^*
Phakic/pseudophakic	24/8	12/6	12/2	0.4^†

Values are mean±SD unless otherwise indicated.
↵* Unpaired t test with Levene's test for equality of variances.
↵† Fisher's exact test.
BCVA, best corrected visual acuity; CNV, choroidal neovascularisation; ETDRS, Early Treatment Diabetic Retinopathy Study.